Synopsis

Source of validity: Scientific
Rating (out of 5): 5

Immunoglobulin G (IgG) therapy is strongly supported by scientific evidence for the treatment and prevention of certain infections, particularly in individuals with primary or secondary immunodeficiencies. IgG, the most abundant antibody in human serum, plays a critical role in immune defense by neutralizing pathogens and facilitating their clearance through opsonization and complement activation. In clinical settings, intravenous or subcutaneous immunoglobulin (IVIG or SCIG) preparations, derived from pooled plasma of healthy donors, are administered to patients with conditions such as X-linked agammaglobulinemia, common variable immunodeficiency, and other disorders where antibody production is impaired.

The efficacy of IgG therapy in reducing the frequency and severity of bacterial infections in these populations is well documented in randomized controlled trials and long-term observational studies. Furthermore, IgG is indicated for specific acute infections, such as certain cases of severe viral infections (e.g., cytomegalovirus, hepatitis B), and for post-exposure prophylaxis against pathogens like hepatitis A and measles in vulnerable populations. Mechanistically, IgG therapy provides passive immunity, supplementing the host's deficient or absent antibody response until their immune system can recover or in cases where it cannot.

Professional guidelines from organizations such as the American Academy of Allergy, Asthma & Immunology and the World Health Organization endorse IgG therapy for infection prophylaxis and treatment in immunodeficient patients. Overall, the use of immunoglobulin G for infection is grounded in robust scientific principles and is supported by a high level of clinical evidence.

More about immunoglobin G
More about Infection

Other ingredients used for Infection

Other health conditions supported by immunoglobin G

Products containing immunoglobin G